ClinicalTrials.gg

Program

ASC36

A development code. Also written as “ASC36 Injection A, for subcutaneous use”, “ASC36 Injection B, for subcutaneous use” and “ASC36 tablets, for oral use”.

Its studies are mostly in Obesity, led by Ascletis Pharma.

Furthest: phase 1, since Oct 19, 20262 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ascletis Pharma22 open or runningphase 1since Oct 19, 2026Oct 19, 2026Apr 2027phase 1 · NCT07893106

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 19, 2026First studies: 2 phase 1 studies in ObesityFirst studyNCT07893106, NCT07893093

Ahead

  1. Apr 2027Primary completion: phase 1 study in ObesityNCT07893106
  2. Jun 2027Primary completion: phase 1 study in ObesityNCT07893093

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07893106Obesity · United States1RecruitingApr 202786
NCT07893093Obesity · United States1RecruitingJun 2027144

How it is read

Names in the registry

  • “ASC36 Injection A, for subcutaneous use”, 1 entry
  • “ASC36 Injection B, for subcutaneous use”, 1 entry
  • “ASC36 tablets, for oral use”, 1 entry

Codes read as this program: ASC36.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.